BR0311714A - Combinações que compreendem epotilonas e seus usos farmacêuticos - Google Patents
Combinações que compreendem epotilonas e seus usos farmacêuticosInfo
- Publication number
- BR0311714A BR0311714A BR0311714-6A BR0311714A BR0311714A BR 0311714 A BR0311714 A BR 0311714A BR 0311714 A BR0311714 A BR 0311714A BR 0311714 A BR0311714 A BR 0311714A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- combination
- treatment
- topoisomerase
- simultaneous
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMBINAçõES QUE COMPREENDEM EPOTILONAS E SEUS USOS FARMACêUTICOS". A presente invenção refere-se a uma combinação farmacêutica que compreende (a) um anticorpo de HER-1 ou HER-2, ou (b) pelo menos um agente antineoplásico selecionado no grupo que consiste em inibidores de aromatase antiestrogênios, inibidores de topoisomerase I, inibidores de topoisomerase II, agentes ativos em microtúbulos, inibidores de proteína cinase C, compostos antiangiogênicos, agonistas de gonadorrelina, antiandrogênios, inibidores de histona desacetilase e inibidores de S-adenosilmetionina descarboxilase; e (c) um derivado de epotilona da fórmula I, e opcionalmente pelo menos um veículo farmaceuticamente aceitável, para uso simultâneo, separado ou seq³encial, particularmente para o tratamento de uma doença proliferativa, especialmente uma doença de tumor sólido; uma composição farmacêutica que compreende tal combinação; o uso de tal combinação para a preparação de um medicamento para o tratamento de uma doença proliferativa; uma embalagem ou produto comercial que compreende tal combinação como uma preparação combinada para uso simultâneo, separado ou seq³encial e um método para tratar um animal de sangue quente, especialmente um ser humano.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38702502P | 2002-06-10 | 2002-06-10 | |
US40623902P | 2002-08-27 | 2002-08-27 | |
US40623802P | 2002-08-27 | 2002-08-27 | |
US43867703P | 2003-01-08 | 2003-01-08 | |
US43867603P | 2003-01-08 | 2003-01-08 | |
PCT/EP2003/005988 WO2003103712A1 (en) | 2002-06-01 | 2003-06-06 | Combinations comprising epothilones and pharmaceutical uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0311714A true BR0311714A (pt) | 2005-03-01 |
Family
ID=29741146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0311714-6A BR0311714A (pt) | 2002-06-10 | 2003-06-06 | Combinações que compreendem epotilonas e seus usos farmacêuticos |
Country Status (17)
Country | Link |
---|---|
US (2) | US20050271669A1 (pt) |
EP (2) | EP1515750B1 (pt) |
JP (1) | JP2005535608A (pt) |
CN (2) | CN101816792A (pt) |
AT (1) | ATE476995T1 (pt) |
AU (1) | AU2003242646A1 (pt) |
BR (1) | BR0311714A (pt) |
CA (1) | CA2487147A1 (pt) |
DE (1) | DE60333754D1 (pt) |
HK (1) | HK1075208A1 (pt) |
IL (1) | IL165180A0 (pt) |
MX (1) | MXPA04012444A (pt) |
NO (1) | NO20050096L (pt) |
PL (1) | PL372070A1 (pt) |
SG (1) | SG162616A1 (pt) |
WO (1) | WO2003103712A1 (pt) |
ZA (1) | ZA200409137B (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2596B1 (en) * | 2004-11-30 | 2011-02-27 | نوفارتيس ايه جي | Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
BRPI0613429A2 (pt) | 2005-07-14 | 2009-02-10 | Takeda San Diego Inc | inibidores de histona desacetilase |
US20080242648A1 (en) * | 2006-11-10 | 2008-10-02 | Syndax Pharmaceuticals, Inc., A California Corporation | COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
WO2009015203A1 (en) * | 2007-07-23 | 2009-01-29 | Syndax Pharmaceuticals, Inc. | Novel compounds and methods of using them |
US20100267779A1 (en) * | 2007-07-23 | 2010-10-21 | Syndax Pharmaceuticals, Inc. | Novel Compounds and Methods of Using Them |
US20090149511A1 (en) * | 2007-10-30 | 2009-06-11 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC and an mTOR Inhibitor |
US20090131367A1 (en) * | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
US20110182888A1 (en) * | 2008-04-08 | 2011-07-28 | Peter Ordentlich | Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator |
EP2571525A4 (en) | 2010-05-18 | 2016-04-27 | Cerulean Pharma Inc | Compositions and methods for treating autoimmune and other diseases |
JP7542947B2 (ja) * | 2016-10-28 | 2024-09-02 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストン脱アセチル化酵素阻害剤及びエポチロンを含む医薬品組み合わせならびにその使用方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5516775A (en) * | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
JP4579351B2 (ja) * | 1996-12-03 | 2010-11-10 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | エポチロンの合成とその中間体及びその類似物並びにその使用 |
MY125921A (en) * | 1998-02-05 | 2006-08-30 | Novartis Ag | Compositions containing organic compounds |
MXPA00008365A (es) * | 1998-02-25 | 2002-11-07 | Sloan Kettering Inst Cancer | Sintesis de epotilonas, intermediarios y analogos de las mismas. |
AU5036999A (en) * | 1998-06-30 | 2000-01-17 | Schering Aktiengesellschaft | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use |
KR20010094763A (ko) * | 1999-02-11 | 2001-11-01 | 에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만 | 에포틸론 유도체, 그 제조방법 및 제약적 용도 |
DE19908760A1 (de) * | 1999-02-18 | 2000-08-24 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO2001064650A2 (en) * | 2000-03-01 | 2001-09-07 | Sloan-Kettering Institute For Cancer Research Center | Synthesis of epothilones, intermediates thereto and analogues thereof |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
DE10020517A1 (de) * | 2000-04-19 | 2001-10-25 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
DE10020899A1 (de) * | 2000-04-20 | 2001-10-25 | Schering Ag | 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten |
PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
CZ305799B6 (cs) * | 2001-03-14 | 2016-03-23 | Bristol-Myers Squibb Company | Kombinace analogů epothilonu a chemoterapeutických činidel pro léčení proliferačních nemocí |
-
2003
- 2003-06-06 SG SG200608597-1A patent/SG162616A1/en unknown
- 2003-06-06 EP EP03757040A patent/EP1515750B1/en not_active Expired - Lifetime
- 2003-06-06 DE DE60333754T patent/DE60333754D1/de not_active Expired - Lifetime
- 2003-06-06 PL PL03372070A patent/PL372070A1/xx not_active Application Discontinuation
- 2003-06-06 AU AU2003242646A patent/AU2003242646A1/en not_active Abandoned
- 2003-06-06 AT AT03757040T patent/ATE476995T1/de not_active IP Right Cessation
- 2003-06-06 BR BR0311714-6A patent/BR0311714A/pt not_active IP Right Cessation
- 2003-06-06 CA CA002487147A patent/CA2487147A1/en not_active Abandoned
- 2003-06-06 US US10/517,074 patent/US20050271669A1/en not_active Abandoned
- 2003-06-06 EP EP20090178302 patent/EP2179745A1/en not_active Withdrawn
- 2003-06-06 WO PCT/EP2003/005988 patent/WO2003103712A1/en active Application Filing
- 2003-06-06 CN CN201010166742A patent/CN101816792A/zh active Pending
- 2003-06-06 JP JP2004510831A patent/JP2005535608A/ja active Pending
- 2003-06-06 CN CN038134489A patent/CN1658904A/zh active Pending
- 2003-06-06 MX MXPA04012444A patent/MXPA04012444A/es active IP Right Grant
-
2004
- 2004-11-11 ZA ZA2004/09137A patent/ZA200409137B/en unknown
- 2004-11-11 IL IL16518004A patent/IL165180A0/xx unknown
-
2005
- 2005-01-07 NO NO20050096A patent/NO20050096L/no unknown
- 2005-08-31 HK HK05107649.5A patent/HK1075208A1/xx not_active IP Right Cessation
-
2010
- 2010-10-20 US US12/908,533 patent/US20110033458A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL165180A0 (en) | 2005-12-18 |
EP2179745A1 (en) | 2010-04-28 |
HK1075208A1 (en) | 2005-12-09 |
US20110033458A1 (en) | 2011-02-10 |
CA2487147A1 (en) | 2003-12-18 |
NO20050096L (no) | 2005-02-04 |
DE60333754D1 (de) | 2010-09-23 |
AU2003242646A1 (en) | 2003-12-22 |
JP2005535608A (ja) | 2005-11-24 |
US20050271669A1 (en) | 2005-12-08 |
ZA200409137B (en) | 2005-08-31 |
MXPA04012444A (es) | 2005-04-19 |
CN1658904A (zh) | 2005-08-24 |
EP1515750B1 (en) | 2010-08-11 |
WO2003103712A1 (en) | 2003-12-18 |
SG162616A1 (en) | 2010-07-29 |
PL372070A1 (en) | 2005-07-11 |
CN101816792A (zh) | 2010-09-01 |
ATE476995T1 (de) | 2010-08-15 |
EP1515750A1 (en) | 2005-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20050096L (no) | Kombinasjoner som innbefatter epotiloner og farmasoytiske anvendelser derav | |
WO2006059234A3 (en) | Bicyclic amides as kinase inhibitors | |
BRPI0508540B8 (pt) | composto, composição farmacêutica, e, uso de um composto | |
EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
NO20055891L (no) | Kinazolinderivater som aurorakinaseinhibitorer | |
HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
EA200401019A1 (ru) | Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества | |
BRPI0507482A (pt) | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap | |
PA8606201A1 (es) | DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
ATE395071T1 (de) | Pharmazeutische zubereitungen zur angiogenese- therapie | |
ECSP084948A (es) | Combinaciones que comprenden epotilonas y sus usos farmaceuticos | |
BR0307588A (pt) | Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença | |
BR9807950A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto | |
BRPI0409884A (pt) | compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
BRPI0409818A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
SE0002729D0 (sv) | Novel compound form | |
EA200501233A1 (ru) | 4-аминопиримидин-5-он | |
BRPI0520806A2 (pt) | derivados pirrólicos, processos para a preparação de compostos, seu uso e composição farmacêutica que os contém | |
UY29561A1 (es) | Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
ECSP045479A (es) | Combinaciones que comprenden epotilonas y sus usos farmaceuticos | |
WO2002059109A3 (en) | Naphthostyril derivatives and their use as inhibitors of cyclin- dependent kinases | |
AR043622A1 (es) | "2- (butil-1 sulfonilamino) - n- [1 (r) - (6 - metoxipiridin - 3 - il - propil] benzamida ,su uso como un medicamento y preparaciones farmaceuticas que lo comprenden | |
RU2004139234A (ru) | Комбинации, включающие эпотилоны, и их фармацевтическое применение | |
BR0312283A (pt) | Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf | |
AR042210A1 (es) | Composicion farmaceutica que contiene antagonistas de leucotrienos b4 (ltb4) e inhibidores de la ciclooxigenasa (cox) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014. |